TUMOR MARKERS IN BONE MARROW IN PATIENTS WITH PROSTATIC CANCER

We compared prostatic specific acid phosphatase (PAP), prostatic specific antigen (PA) and γ-seminoprotein (γ-SM) levels between bone marrow and serum for the purpose of assessing of the usefulness of these tumor markers in early detection of bone metastasis in cases with prostatic cancer. Thirty-three patients were entered into this study. Of the patients, 20 had prostatic cancer including 11 with bone metastasis, and 13 patients had benign prostatic hypertrophy (BPH) served as controls. It seemed unlikely that bone marrow PAP, PA and γ-SM are more useful than their serum levels for detection of bone metastasis of prostatic cancer. Because correlation between bone marrow and serum levels of each marker was observed not only in cases with prostate cancer accompanied by bone metastasis but also in metastasis-free prostatic cancer and BPH cases, it seems likely that PAP, PA and γ-SM in bone marrow circulate from peripheral blood rather than from bone metastasis of prostatic cancer

根治的前立腺摘除術による排尿機能への影響排尿筋機能に焦点をおいた前向きの尿流動態学的検討

17名の前立腺癌患者の術後の排尿機能への影響につき蓄尿期ならびに排出期の膀胱内圧測定を含めた泌尿器科学的評価をとおしてprospectiveに臨床的検討を行った.その結果, 術後3ヵ月の時点で排尿筋機能がweakと判定された症例は, それ以外の症例と比較して有意に尿失禁の割合が高かった(p<0.05).また, 3ヵ月以上尿失禁が持続した8名のうち, 7名(88%)は術後3ヵ月の時点で排尿筋機能はweak detrusorと診断された症例であった.それらのうち4名は術前評価では, 排尿筋機能はnormal detrusorと評価された症例であった.これらの症例では最大尿流量率が低下しており, また, 他の症例群に比較して有意にQOLスコアの悪化を認めた(p<0.05).以上, これらのことからも, 遷延する尿失禁や尿勢低下を伴う患者において排尿筋機能に影響する薬物治療を行う際には, 術前の排尿筋機能にかかわらず注意が必要であることが示唆された.また, 術後QOLを考慮するとき, 排尿筋機能も含めた尿流動態評価に基づいた適切な排尿管理を行うことが重要であると考えられたProstate cancer is common in aged men and radical prostatectomy is established as a therapeutic measure. However, to date there is little information about its impact on voiding function. We conducted a prospective clinical study to elucidate the impact of radical prostatectomy on voiding function in 17 patients with prostate cancer, by urological evaluation including filling and voiding cystometry (pressure flow study). The patients who were estimated as having weak detrusor function including very weak detrusor function at 3 months postoperatively had significantly more frequent urinary incontinence compared with the others (p < 0.05). Of 8 patients who showed urinary incontinence for more than 3 months, 7 (88%) patients developed weak detrusor function at 3 months after operation, but 4 of them were estimated as having normal detrusor function preoperatively. These patients revealed reduced maximum flow rate and significantly increased quality of life score compared with the other patients (p < 0.05). An initially reduced bladder compliance disclosed a tendency to a rapid return to normal with time after surgery. Detrusor overactivity itself and neoadjuvant antiandrogen therapy were not related to prolonged postoperative urinary incontinence. The present study indicates that caution is required when administering medication that could potentially affect detrusor function, regardless of the type of preoperative detrusor function, in patients with persistent urinary incontinence or a reduced urinary stream. Particular emphasis is laid on the importance of urodynamic assessment of post-prostatectomy detrusor function and appropriate management modalities based on the results

Additional file 2: Figure S2. of Functional analysis of fatty acid binding protein 7 and its effect on fatty acid of renal cell carcinoma cell lines

Proliferation of TUHR14TKB cells transfected with an FABP7 expression vector. The proliferation of cells transfected with the FABP7 expression vector or lacZ expression vector was determined using an MTS assay. The data represent of five experiments. Transfectants were cultured in RPMI 1640 medium containing 5 mg/L blasticidin S HCl, 0.3 g/L G418, and 1 mg/L doxycycline hyclate with 1% FBS (a-b) or 10% FBS (c-d). a, c, TUHR14TKB lacZ. b, d, TUHR14TKB FABP7. (TIFF 1521 kb

Analysis of the regulation of fatty acid binding protein 7 expression in human renal carcinoma cell lines

<p>Abstract</p> <p>Background</p> <p>Improving the treatment of renal cell carcinoma (RCC) will depend on the development of better biomarkers for predicting disease progression and aiding the design of appropriate therapies. One such marker may be fatty acid binding protein 7 (FABP7), also known as B-FABP and BLBP, which is expressed normally in radial glial cells of the developing central nervous system and cells of the mammary gland. Melanomas, glioblastomas, and several types of carcinomas, including RCC, overexpress FABP7. The abundant expression of FABP7 in primary RCCs compared to certain RCC-derived cell lines may allow the definition of the molecular components of FABP7's regulatory system.</p> <p>Results</p> <p>We determined <it>FABP7 </it>mRNA levels in six RCC cell lines. Two were highly expressed, whereas the other and the embryonic kidney cell line (HEK293) were weakly expressed <it>FABP7 </it>transcripts. Western blot analysis of the cell lines detected strong FABP7 expression only in one RCC cell line. Promoter activity in the RCC cell lines was 3- to 21-fold higher than that of HEK293. Deletion analysis demonstrated that three <it>FABP7 </it>promoter regions contributed to upregulated expression in RCC cell lines, but not in the HEK293 cell. Competition analysis of gel shifts indicated that OCT1, OCT6, and nuclear factor I (NFI) bound to the <it>FABP7 </it>promoter region. Supershift experiments indicated that BRN2 (POU3F2) and NFI bound to the <it>FABP7 </it>promoter region as well. There was an inverse correlation between <it>FABP7 </it>promoter activity and <it>BRN2 </it>mRNA expression. The FABP7-positive cell line's NFI-DNA complex migrated faster than in other cell lines. Levels of <it>NFIA </it>mRNA were higher in the HEK293 cell line than in any of the six RCC cell lines. In contrast, <it>NFIC </it>mRNA expression was lower in the HEK293 cell line than in the six RCC cell lines.</p> <p>Conclusions</p> <p>Three putative <it>FABP7 </it>promoter regions drive reporter gene expression in RCC cell lines, but not in the HEK293 cell line. BRN2 and NFI may be key factors regulating the expression of FABP7 in certain RCC-derived cell lines.</p